Search
 

Orexigen talks FDA on speeding Contrave review

Orexigen Therapeutics Inc. said Monday it is in discussions with the Food and Drug Administration about speeding up a regulatory review of Orexigen's obesity drug Contrave.

X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.

SAN DIEGO (AP) — Orexigen Therapeutics Inc. said Monday it is in discussions with the Food and Drug Administration about speeding up a regulatory review of Orexigen’s obesity drug Contrave.

Shares rose 30 cents, or 4.9 percent, to $6.45 in premarket trading.

Complete your profile to continue reading and get FREE access to BenefitsPRO.com, part of your ALM digital membership.

Your access to unlimited BenefitsPRO.com content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Critical BenefitsPRO.com information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events.
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com

Already have an account?

Recommended Stories

BenefitsPRO

Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!

  • Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
  • Exclusive discounts on BenefitsPRO.com and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.